Research lines

VivaCell is committed to discover and to develop new natural-derived drugs, specially phytocannabinoids, for the treatment of chronic inflammatory and neurodegenerative diseases. VivaCell has developed a secuential platform of primary and secondary screenings that are able to analyse more than 20 key molecular targets in inflammation and cancer pathways. We are expert in screening of hit compounds, identification of mechanism of action and assessment of the efficacy of molecules and phytoextracts for pharmaceutical, nutraceutical and cosmetic uses.

Currently we have three R&D programs ongoing:

The specific aims of our R&D programs are:

  • Development of VCE-003 and VCE-004 Series in neurodegenerative diseases.
  • Development of VCE-004 Series in Scleroderma.
  • Discovery and development of new VCE-003 derivatives.
  • Discovery and development of new Triterpenoids for therapeutic use.
  • Development of CDE-001 for improvement of skin conditions.

 

Additionally, VivaCell R&D is in continuous growth with the assessment of new molecules and new indications. Our candidates have been developed in our own laboratories and we maintain open programs in collaboration with top Research Institutes and Universities around Europe.

To optimize our know-how, we are pleased to work in collaboration with the CRO and Geman company VivaCell Biotechnology GmbHPlease do not hesitate to contact us whether you would like to know if we can help you to develop your products.

 

.
Developed with DoPlanning